248 related articles for article (PubMed ID: 34863587)
21. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
22. Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.
Penkert J; Strüwe FJ; Dutzmann CM; Doergeloh BB; Montellier E; Freycon C; Keymling M; Schlemmer HP; Sänger B; Hoffmann B; Gerasimov T; Blattmann C; Fetscher S; Frühwald M; Hettmer S; Kordes U; Ridola V; Kroiss Benninger S; Mastronuzzi A; Schott S; Nees J; Prokop A; Redlich A; Seidel MG; Zimmermann S; Pajtler KW; Pfister SM; Hainaut P; Kratz CP
J Hematol Oncol; 2022 Aug; 15(1):107. PubMed ID: 35974385
[TBL] [Abstract][Full Text] [Related]
23. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
24. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
25. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre.
Butz H; Bozsik A; Grolmusz V; Szőcs E; Papp J; Patócs A
Sci Rep; 2023 Aug; 13(1):14259. PubMed ID: 37653074
[TBL] [Abstract][Full Text] [Related]
26. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
27. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
28. Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome.
Park KJ; Choi HJ; Suh SP; Ki CS; Kim JW
Ann Lab Med; 2016 Sep; 36(5):463-8. PubMed ID: 27374712
[TBL] [Abstract][Full Text] [Related]
29. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
31. Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.
de Andrade KC; Mirabello L; Stewart DR; Karlins E; Koster R; Wang M; Gapstur SM; Gaudet MM; Freedman ND; Landi MT; Lemonnier N; Hainaut P; Savage SA; Achatz MI
Hum Mutat; 2017 Dec; 38(12):1723-1730. PubMed ID: 28861920
[TBL] [Abstract][Full Text] [Related]
32. A Rare
Powers J; Pinto EM; Barnoud T; Leung JC; Martynyuk T; Kossenkov AV; Philips AH; Desai H; Hausler R; Kelly G; Le AN; Li MM; MacFarland SP; Pyle LC; Zelley K; Nathanson KL; Domchek SM; Slavin TP; Weitzel JN; Stopfer JE; Garber JE; Joseph V; Offit K; Dolinsky JS; Gutierrez S; McGoldrick K; Couch FJ; Levin B; Edelman MC; Levy CF; Spunt SL; Kriwacki RW; Zambetti GP; Ribeiro RC; Murphy ME; Maxwell KN
Cancer Res; 2020 Sep; 80(17):3732-3744. PubMed ID: 32675277
[TBL] [Abstract][Full Text] [Related]
33. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract][Full Text] [Related]
34. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
[TBL] [Abstract][Full Text] [Related]
35. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
36. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
37. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
[TBL] [Abstract][Full Text] [Related]
38. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
[TBL] [Abstract][Full Text] [Related]
39. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
